Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-Current Deffered Revenue (2022 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $35.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $35.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $35.0 million, a 0.0% change, with the full-year FY2023 number at $35.0 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue was $35.0 million for Q3 2024 at Actinium Pharmaceuticals, roughly flat from $35.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $35.0 million in Q4 2022 to a low of $35.0 million in Q4 2022.
  • A 3-year average of $35.0 million and a median of $35.0 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2023; the steepest drop was 0.0% in 2023.
  • Actinium Pharmaceuticals' Non-Current Deffered Revenue stood at $35.0 million in 2022, then changed by 0.0% to $35.0 million in 2023, then changed by 0.0% to $35.0 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Non-Current Deffered Revenue are $35.0 million (Q3 2024), $35.0 million (Q2 2024), and $35.0 million (Q1 2024).